Anemia is a significant and frequent comorbidity in heart failure patients with a strong negative prognostic impact. It ‘s clear the poor attention paid to identify the cause of anemia, its monitoring over time and its treatment. Current therapies, which in any case have an impact on health care costs, are poorly managed and are not sufficiently effective. In fact, only an absolutely insignificant proportion of patients (11%) reach the therapeutic target, and in any case the increase in Hb values does not improve prognosis, especially in terms of re-hospitalization reduction. There is therefore clearly an unmet need, which could be corrected by innovative therapeutic strategies.
Anemia management in heart failure patients:data from the observational registry CARMES 1” / Caira, Carmen; Gatto, M. C.; Pagliaro, Michela; L., Fratarcangeli; Canali, Emanuele; Centurion Aznaran, C. A.; R., Di Pietro; V., Di Spirito; G., Ansalone; Fedele, Francesco. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - STAMPA. - Supplements 2012; Vol. 11 (1):(2012).
Anemia management in heart failure patients:data from the observational registry CARMES 1”
CAIRA, CARMEN;PAGLIARO, MICHELA;CANALI, EMANUELE;FEDELE, Francesco
2012
Abstract
Anemia is a significant and frequent comorbidity in heart failure patients with a strong negative prognostic impact. It ‘s clear the poor attention paid to identify the cause of anemia, its monitoring over time and its treatment. Current therapies, which in any case have an impact on health care costs, are poorly managed and are not sufficiently effective. In fact, only an absolutely insignificant proportion of patients (11%) reach the therapeutic target, and in any case the increase in Hb values does not improve prognosis, especially in terms of re-hospitalization reduction. There is therefore clearly an unmet need, which could be corrected by innovative therapeutic strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
